Direct-to-consumer genetic testing company 23andMe used customer data and volunteered health information from customers to confirm over 180 known genetic associations with diseases and human characteristics. As the number of people who have gotten themselves genetically tested goes up by orders of magnitude so too will the ability of genetic testing services provides to find more associations between genes and assorted diseases and attributes of humans.
MOUNTAIN VIEW, CA – (August 17, 2011) – 23andMe, Inc., a leading personal genetics company has replicated over 180 genetic associations from a list of associations curated by the National Human Genome Research Institute’s Office of Population Genomics ("GWAS Catalog") demonstrating that self-reported medical data is effective and reliable to validate known genetic associations. The results, available online in the journal PLoS ONE, establish 23andMe's methodology as a significant research platform in a new era of genetic research.
"In this paper we confirm that self reported data from our customers has the potential to yield data of comparable quality as data gathered using traditional research methods," stated 23andMe Chief Business Officer Ashley Dombkowski. "As the 23andMe platform has been clearly shown to replicate known genetic associations as well as discover new ones, we have established our research platform as an innovative model for genetic research which has the power to move scientific research forward faster and more cost effectively working in collaboration with academic and commercial researchers," continued Dombkowski.
I think we are going to reach a stage where most research on identifying functional significance of human genetic variations will be done as a result of people donating their genetic test results and health and other information to researchers. The cost of genetic testing has fallen so far that most genetic testing will be funded by individuals just wanting to get their own personal genetic information. The only thing that could stop this better future? A clamp-down on direct-to-consumer genetic testing by US Food and Drug Administration. The FDA should be encouraged to stay out of the way of progress. Tell your Congress critters.
|Share |||Randall Parker, 2011 August 19 10:30 AM Biotech Assay Services|